Standard doses of linezolid may not be suitable for all patient groups. Intensive care unit (ICU) patients in particular may be at risk of inadequate concentrations. This study investigated variability of drug exposure and its potential sources in this population.
Plasma concentrations of linezolid were determined by high-performance liquid chromatography in a convenience sample of 20 ICU patients treated with intravenous linezolid 600 mg twice daily. Ultrafiltration applying physiological conditions (pH 7.4/37°C) was used to determine the unbound fraction. Individual pharmacokinetic (PK) parameters were estimated by population PK modeling. As measures of exposure to linezolid, area under the concentration–time curve (AUC) and trough concentrations (Cmin) were calculated and compared with published therapeutic ranges (AUC 200–400 mg*h/L, Cmin 2–10 mg/L). Coadministered inhibitors or inducers of cytochrome P450 and/or P-glycoprotein were noted.
Data from 18 patients were included into the PK evaluation. Drug exposure was highly variable (median, range: AUC 185, 48–618 mg*h/L, calculated Cmin 2.92, 0.0062–18.9 mg/L), and only a minority of patients had values within the target ranges (6 and 7, respectively). AUC and Cmin were linearly correlated (R = 0.98), and classification of patients (underexposed/within therapeutic range/overexposed) according to AUC or Cmin was concordant in 15 cases. Coadministration of inhibitors was associated with a trend to higher drug exposure, whereas 3 patients treated with levothyroxine showed exceedingly low drug exposure (AUC ∼60 mg*h/L, Cmin <0.4 mg/L). The median unbound fraction in all 20 patients was 90.9%.
Drug exposure after standard doses of linezolid is highly variable and difficult to predict in ICU patients, and therapeutic drug monitoring seems advisable. PK drug–drug interactions might partly be responsible and should be further investigated; protein binding appears to be stable and irrelevant.
*Department of Anaesthesiology and Intensive Care, Charité Universitätsmedizin Berlin—Campus Benjamin Franklin, Berlin, Germany;
†Department of Clinical Pharmacy, Institute of Pharmacy, University of Regensburg, Regensburg, Germany;
‡Hospital pharmacy, University Hospital Regensburg, Regensburg, Germany;
§Department of Pharmaceutical Biosciences, Uppsala Universitet, Uppsala, Sweden;
¶Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany;
‖Department of Pharmacology, University of Regensburg, Regensburg, Germany; and
#Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
Correspondence: Martin G. Kees, MD, Department of Anesthesiology and Intensive Care, Charité Universitätsmedizin Berlin—Campus Benjamin Franklin, Hindenburgdamm 30, Berlin 12200, Germany (e-mail: firstname.lastname@example.org).
This work was funded by institutional sources only.
The authors declare no conflict of interest.
Received April 20, 2016
Accepted July 15, 2016